Health Canada Study reports [Regulatives / Guidelines]

posted by anky1212 – India, 2019-02-21 05:05  – Posting: # 19951
Views: 275

Dear All,

As per Health canada guidance document, "To avoid study bias, comparative bioavailability studies should be conducted in such a way that the subjects are not aware of which product (test or reference) is being administered. Furthermore, the persons checking for adverse reactions and those conducting the bioanalysis of samples should not know the treatment sequence."

In this case, if adverse events is ongoing, analysis both analytical and statistical phase completed, shall we submit treatment or code in study report?

Upto which phase guidance is applicable?

After completion of statistical phase if adverse event is still ongoing, still we need to follow guidance?

Thanks
Ankur Patel

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,490 posts in 4,135 threads, 1,336 registered users;
online 5 (0 registered, 5 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 14:55 CEST

No rational argument will have a rational effect on a man
who does not want to adopt a rational attitude.    Karl R. Popper

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5